Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
The main purpose of this study is to see if the study drug, PTK787, is safe and to find the highest dose that can be given safely without causing serious side effects.
Ovarian Cancer|Endometrial Cancer|Cervical Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Breast Cancer
DRUG: Docetaxel|DRUG: PTK787
To determine the maximum tolerated dose and the dose limiting toxicity of weekly Taxotere patients treated with PTK787., 2 years
To estimate the preliminary efficacy of this combination in both metastatic breast cancer patients and refractory gynecological patients., 2 years
* Patients will come to the clinic once a week to receive study treatment. To help reduce the chance of an allergic reaction patients will take Decadron tablets orally the night before, the morning of and the evening of receiving chemotherapy.
* The lead-in schedule of dosing is as follows: Day 1: Taxotere intravenously; Day 4: PTK787 orally; Day 14: Taxotere and PTK787.
* After the lead-in schedule, a cycle will consist of 28 days. PTK787 will be given orally once a day without interruption. Taxotere will be given on Day 1, Day 8, Day 15 and Day 22.
* Before each dose of Taxotere, blood tests, urine tests, and a physical exam will be done. A radiological evaluation will be done every two months. If the patients tumor remains stable or shrinks in size, they may continue to stay on the study.
* Patients should not eat grapefruit or drink grapefruit juice during this study.